Recombinant Human VSIG1 Fc Chimera Protein, CF

Recombinant Human VSIG1 Fc Chimera (Catalog # 9708‑VS)inhibits IL-17 secretion by human peripheral blood mononuclear cells (PBMC) inthe presence of anti-CD3 antibody. The ED50 for this effect is 5-25 μg/mL.

• Reactivity: Hu
• Applications: Bioactivity
• Format: Carrier-Free

Recombinant Human VSIG1 Fc Chimera Protein, CF Summary

• Details of Functionality: Measured by its ability to inhibit anti-CD3 antibody induced IL-17 secretion by human peripheral blood mononuclear cells (PBMC). The ED₅₀ for this effect is 5-25 μg/mL.
• Source: Mouse myeloma cell line, NS0-derived human VSIG1 protein
  

  Human VSIG1 (Val22-Gly234) Accession # Q86XK7-1	IEGRMD	Human IgG1 (Pro100-Lys330)
  N-terminus		C-terminus

• Accession #: Q86XK7-1
• N-terminal Sequence: Val22
• Structure / Form: Disulfide-linked homodimer
• Protein/Peptide Type: Recombinant Proteins
• Purity: >95%, by SDS-PAGE visualized with Silver Staining and quantitative densitometry by Coomassie® Blue Staining.
• Endotoxin Note: <0.10 EU per 1 μg of the protein by the LAL method.

Applications/Dilutions

• Dilutions:
  • Bioactivity
• Theoretical MW: 50 kDa.
  Disclaimer note: The observed molecular weight of the protein may vary from the listed predicted molecular weight due to post translational modifications, post translation cleavages, relative charges, and other experimental factors.
• SDS-PAGE: 68-84 kDa, reducing conditions

Packaging, Storage & Formulations

• Storage: Use a manual defrost freezer and avoid repeated freeze-thaw cycles.
  • 12 months from date of receipt, -20 to -70 °C as supplied.
  • 1 month, 2 to 8 °C under sterile conditions after reconstitution.
  • 3 months, -20 to -70 °C under sterile conditions after reconstitution.
• Buffer: Lyophilized from a 0.2 μm filtered solution in PBS.
• Purity: >95%, by SDS-PAGE visualized with Silver Staining and quantitative densitometry by Coomassie® Blue Staining.
• Reconstitution Instructions: Reconstitute at 200 μg/mL in PBS.

Notes

This product is produced by and ships from R&D Systems, Inc., a Bio-Techne brand.

Alternate Names for Recombinant Human VSIG1 Fc Chimera Protein, CF

• Cell surface A33 antigen
• dJ889N15.1
• Glycoprotein A34
• GPA34
• MGC44287,1700062D20Rik
• V-set and immunoglobulin domain containing 1
• V-set and immunoglobulin domain-containing protein 1
• VSIG1

Background

VSIG1 (V-set and immunoglobulin domain-containing protein 1), also known as Glycoprotein A34, is a member of the JAM (junctional adhesion molecule) family of proteins (1, 2). It is predominantly expressed in stomach and testis, and was also detected in gastric, esophageal and ovarian cancers (2). VSIG1 is required for the proper differentiation of glandular gastric epithelia, and also plays a role as tumor suppressor (3, 4). This type I transmembrane glycoprotein consists of a 21 aa signal peptide, a 211 aa extracellular domain (ECD), a 21 aa transmembrane domain and 134 aa cytoplasmic domain. Within the ECD, human VSIG1 shares 81% and 83% amino acid sequence identity with mouse and rat VSIG1, respectively. Our studies at R&D Systems show that VSIG1 inhibits T cell activation, including IL-17 and Interferon gamma production.

1. Kim, E. et al. (2010) Mol. Cells 30:443.
2. Scanlan, M.J. et al. (2006) Cancer Immun. 6:2.
3. Oidovasambuu, O. (2011) PLoS One 10:e25908.
4. Inoue, Y. et al. (2017) Cancer Sci. 8:1701.

Bioinformatics

• Uniprot:
  • Q86XK7-1()